and,likeFBDpatients,FBD KI mice carry this mutation in one of the two murine Bri2 alleles. We report that the British mutation drastically reduces expression of mature BRI2 in both KI mice and human FBD brains. This deficit is associated with severe hippocampal memory deficits in FBD KI mice. Remarkably, these animals showed no cerebral amyloidosis and tauopathy. Bri2 ϩ/ Ϫ mice present memory deficits similar to those in FBD KI animals. Collectively, these results indicate that the British BRI2 mutation underlies abnormal memory due to loss of BRI2 function and independently of histopathological alterations typically evident in advanced neurodegenerative disease.
Introduction
BRI2 is a type II transmembrane protein that belongs to a multigene family comprising BRI1, BRI2 and BRI3 (also referred to as ITM2A, ITM2B and ITM2C, or E25A, E25B and E25C, respectively) (Deleersnijder et al., 1996; Pittois et al., 1999; Vidal et al., 1999 Vidal et al., , 2000 in both mice and human. It possesses a BRICHOS domain, a conserved motif common to members of the BRI, ChM-I, SP-C and CA11 protein families, thought to have a role in the targeting of proteins to the secretory pathway or to intracellular processing (Sánchez-Pulido et al., 2002) . Proteins sharing the BRICHOS motif associate with a diverse range of phenotypes, varying from dementia to cancer and respiratory distress.
BRI2 was originally described in relation to Familial British Dementia (FBD) (Vidal et al., 1999) , an autosomal dominant neurodegenerative disease characterized by the early onset of personality changes, memory and cognitive deficits, spastic rigidity, and ataxia. In FBD, a proteolytic C-terminal 34 aa fragment of BRI2, called ABri, accumulates leading to severe amyloid angiopathy of the brain and spinal cord with perivascular amyloid plaque formation, parenchymal plaques affecting the limbic areas, cerebellum cerebral cortex, neurofibrillary degeneration of hippocampal neurons and changes of the periventricular white matter (Plant et al., 1990) . A distinct mutation causes a similar autosomal dominant neurodegenerative disorder, Familial Danish Dementia (FDD) (Vidal et al., 2000) . BRI2 is physiologically cleaved, at the C terminus, by a proprotein convertase producing a 23 aa soluble C-terminal fragment. In FBD, a single base substitution at the stop codon of BRI2 generates a longer open reading frame, resulting in a larger, 277 aa precursor (compared with the 266 aa normal allele). The outcome of this genetic defect is the generation of the longer amyloidogenic C-terminal fragment ABri (Vidal et al., 1999) .
Several neuropathological features are common to FBD, FDD and AD: amyloid deposition neurofibrillary tangles (Holton et al., 2001 Rostagno et al., 2002) , neurodegeneration, and accumulation of complement proteins and their proinflammatory activation products, including iC3b, C4d, Bb, and C5b-9.
Mouse models are critical to explore both pathogenesis and therapy of human diseases. All animal models used to study human neurodegenerative diseases consist of transgenic mice carrying mutant forms of genes shown to be involved in human dementia (LaFerla and Oddo, 2005; McGowan et al., 2006; Vidal et al., 2009; Coomaraswamy et al., 2010) . A serious limitation of these models is that their design is predicated on the assumption that development of amyloid plaques and neurofibrillary tangles is directly related to the cognitive and behavioral changes associated with human dementia. However, this hypothesis is yet to be proven since other mechanisms, such as for example loss of function due to pathogenic mutations could cause or contribute to the pathogenesis of human dementia. Evidence suggests that loss of function could be pathogenic in neurodegenerative diseases. Mutations in PSEN1/PSEN2, which cause familial AD, reduce PSEN1/PSEN2 function (De Strooper, 2007) and deletion of PSEN1/PSEN2 in mouse brains causes neurodegeneration, synaptic dysfunction and memory loss (Saura et al., 2004; Zhang et al., 2009 ). Since such mechanisms cannot be uncovered by a transgenic approach due to the persistence of the endogenous wild-type (WT) alleles, we generated a genetically coherent KI animal model of FBD, called FBD KI . The analysis of both anatomical and clinical pathology of FBD KI mice questions the validity of the "amyloid cascade hypothesis" and suggests that clinical pathology precedes amyloid and tangles pathology in FBD. Thus, this new mouse model provides a powerful system to gain insights into the molecular basis of human neurodegenerative disorders.
Materials and Methods
Ethics statement. Mice were maintained on a C57BL/6 background for several generations (at least 15). Mice were handled according to the Ethical Guidelines for Treatment of Laboratory Animals of Albert Einstein College of Medicine. The procedures were described and approved in animal protocol number 20040707. Mice were killed by cervical dislocation after isoflurane anesthesia.
Bri2 knock-in construction. The targeting strategy for the generation of the FBD KI mice is similar to that used to generate the FDD KI mice (Giliberto et al., 2009 ) and entails the replacement of the Bri2 exon 6 with a mutated exon 6 carrying the FBD mutation. Differently from the FD-D KI , we produced a 332 bp fragment containing the ABri mutation (t798a substitution, leading to a Stop3 R transition at codon 267 and to the introduction of an XbaI site at nucleotide 799), plus a humanizing substitution a3g (acc3gcc ϭ Threonine3 Alanine) at the 12th codon of exon 6, by serial PCRs, using pBS-Ex3-6 HindIII as a template (Giliberto et al., 2009) . Similarly to the FDD KI mice, we obtained the construct-Right Arm-LoxP1-PGK-Neomycin cassette-LoxP2-Left Arm-dTA cassette-which was linearized with SalI, purified injected in ES cells strain 129 by electroporation. Selection of the clones in which the construct had integrated properly by homologous recombination was by means of G418 (200 g/ml), through the Neo cassette, and by means of dTA exclusion. Injection of the two Danish ES cell clones into C57BL/6J blastocysts was performed at the Albert Einstein College of Medicine genetargeting facility, according to the current facility protocol (http://www. aecom.yu.edu/home/SharedFacilities/ViewFacility.asp?IDϭ30). The subsequent PCR analysis on the ES clones and mice, the sequencing, and the Southern blot analysis are similar to the ones described earlier (Giliberto et al., 2009 ) and yielded similar results. The FBDKI mice studied here consist of two knock-in lines derived from two distinct recombinant ES clones that have given rise to germ-line transmission of the mutation. Therefore the phenotype of the mice cannot be attributable to a specific mutation cosegregating with the British mutation in one ES clone. The targeting vector sequence has been deposited in GenBank with provisory accession number HM357235.
General pathology. After anesthesia, WT and FBD KI/KI animals were perfusion-fixed with 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.2 (Sigma), after which brains and organs were removed, embedded in paraffin, and sectioned. Eight micrometer sections were cut and mounted on poly-L-lysine-coated slides. After deparaffination in xylene and rehydration, sections were stained with hematoxylin and eosin (H&E) and Congo Red by standard methods. Mineralization was visualized in H&E sections as a deep basophilic amorphous and/or granular material.
Brain histology and immunohistochemistry. Sections from WT and FBD KI/KI animals prepared as above were stained with the H&E, Congo red, and Thioflavin S (ThS) methods. Immunohistochemical stainings were performed as described previously ) by using primary antibodies directed against the following antigens: glial fibrillary acidic protein (GFAP) (Dako), ubiquitin (Dako), amyloid ␤ protein (A␤) clone 4G8 (Signet Laboratories); microtubule-associated protein tau phosphorylated at Ser202/Thr205 (AT8, Pierce Biotechnology, Rockford, IL), keratan sulfate (5D4, Seikagaku Kogyo, Japan), and ABri amyloid peptide (Ab 1705) . The sections were counterstained with cresyl violet or H&E. As control sections from a patient with FBD were run in parallel (kindly provided by Dr. Tamas Revest, University College London, London, UK). For Tau, NeuN and Iba1 immunostaining was performed in sections of the olfactory bulb, hippocampus, temporal cortex, brainstem and cerebellum. After rehydration, endogenous peroxidases were quenched with 95% methanol plus 5% hydrogen peroxide for 30Ј. Antigen retrieval was performed with microwave treatment in citrate buffer (10 mM NaCitrate, pH 6.0), 7 min at maximum power plus 7 min at 60% power. Nonspecific binding was blocked with 5% milk-TBS for 1 h at room temperature. Primary antibodies are as follows: NeuN (Invitrogen #187373, 1/1000), IbA1 (Wako #019-19741, 1/1500), and nonpurified anti-Tau antibodies DA9 (1/5000), CP13 (1/5000), PHF1 (1/5000), all diluted in 5% milk-TBS, and left overnight at 4°C, shaking. Immunostaining was visualized using the avidin-biotin system (Vectastain; Vector Laboratories) and 3,3Ј-diaminobenzidine (Sigma) as the chromogen.
Human and mouse brain, and synaptosome preparations. Brain samples from humans, FBD KI mice, and WT littermates were prepared by homogenizing brains (w/v, 10 mg of tissue/100 l of buffer) in HEPESsucrose buffer (20 mM HEPES/NaOH, pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.25 M sucrose) supplemented with protease and phosphatase inhibitors (PI and PhI). The postnuclear supernatant (PNS) was prepared by precipitating the nuclei and debris by centrifuging the homogenates at 1000 ϫ g for 10 min. Twenty micrograms of each PNS were loaded by SDS-PAGE. APP and BRI2 (wild-type and Danish mutants) were detected by 22C11 (Millipore Bioscience Research Reagents, MAB348) or BRI2 antibody (Akiyama et al., 2004) . For synaptic preparations, mouse brain was homogenates were centrifuged at 800 ϫ g for 10 min. The supernatant (S1) was separated to supernatant (S2) and pellet (P2) by spinning at 9200 ϫ g for 15 min. P2 was lysed on ice for 30 min in H buffer containing 35.6 mM sucrose. The lysed P2 was separated to supernatant (LS1) and pellet (LP1) by spinning at 25,000 ϫ g for 20 min. S2 and LS1 were separated to supernatants (S3 and LS2) and pellet (P3 and LP2) by spinning at 165,000 ϫ g for 2 h, respectively. P3 and LP2 were suspended in H buffer containing 35.6 mM sucrose by sonication. Synaptosome fractions represent: S1, postnuclear supernatant; S2, cytosol, soluble proteins and light membrane; P2, crude synaptosome fraction; S3, soluble fraction; P3, light membrane abundant in Golgi and ER; LS1, crude synaptic soluble; LP1, synaptic membrane fraction; LS2, synaptic soluble; LP2, synaptic vesicle fraction.
Bain preparation for soluble Tau Western blot. Brain homogenates were sonicated 3 times for 20 min in ice, spun 20 min at 20,000 ϫ g at 4°C, and the supernatant was saved. Tau antibodies were diluted in 5% dried Tau ELISA. Clear, flat-bottom, 96 well plates were coated overnight with an antibody specific for total Tau (DA31), 2 g/ml in coating buffer (containing, in mM: 230 K 2 HPO 4 , 135 KH 2 PO 4 , 130 NaCl, 2 EDTA, 0.05% NaN 3 , pH 7.2). Wells were blocked with 100% starting block (Pierce) for 1 h at room temperature. Homogenates were then added: brain homogenates, prepared as described above, were mixed 1/1 with 0.1% SDS, briefly vortexed, and spun for 10 min at 20,000 ϫ g, at room temperature, and the supernatant was loaded on the ELISA plate at 1/250 -1/2000 dilution in 20% Superblock-TBS (Pierce) as needed, and left overnight, at 4°C, gently shaking. Purified primary antibodies were added to the plate, diluted in 20% Superblock-TBS, as follows: biotinylated DA9 (IgG1) 1/5000, CP13 (IgG1) 1/500, biotinylated CP17 (IgG3) 1/20,000 and biotinylated PHF1 (IgG1) 1/10,000, and left for 2 h at room temperature, gently shaking. Secondary antibodies, streptavidin-HRP 1/5000, and HRP-goat anti-mouse IgG1 1/20,000 for CP13 only, were diluted in 20% Superblock-TBS (Pierce), left on the plate for 1 h as above. Fifty microliters of TMB (Pierce) were added and left for 20 min, at room temperature, light shielded, gently shaking, and the reaction was stopped with the same volume of 2 M sulfuric acid and read at 450 nm with an automated Tecan plate reader. Every step was followed by 5 automated washes with washing buffer (100 mM NaCl, 10 mM Tris base, 0.1% Tween 20).
Spatial working memory. The task studied with the radial arm water maze (RAWM) test has been described previously (Trinchese et al., 2004) . Briefly, a six-armed maze was placed into a white tank filled with water (24 -25°C) and made opaque by the addition of nontoxic white paint. Spatial cues were presented on the walls of the testing room. At the end of one of the arms was positioned a clear 10 cm submerged platform that remained in the same location for every trial in 1 d but was moved approximately randomly from day to day. On each trial, the mouse started the task from a different randomly chosen arm. Each trial lasted 1 min, and errors were counted each time the mouse entered the wrong arm or needed Ͼ20 s to reach the platform. After each error, the mouse was pulled back to its starting position. After four consecutive acquisition trials, the mouse was placed in its home cage for 30 min, then returned to the maze and administered a fifth retention trial. The scores for each mouse on the last 3 d of testing were averaged and used for statistical analysis.
Visible platform testing. Visible platform training to test visual and motor deficits was performed in the same pool as in the RAWM; however, the arms of the maze were removed. The platform was marked with a black flag and positioned randomly from trial to trial. Time to reach the platform and speed were recorded with a video tracking system (HVS 2020; HVS Image).
Open field and novel object recognition. After 30 min to acclimate to the testing room, each mouse was placed into a 40 cm ϫ 40 cm open field chamber with 2 feet high opaque walls. Each mouse was allowed to habituate to the normal open field box for 10 min, and repeated again 24 h later, in which the video tracking system (HVS 2020; HVS Image) quantifies the total distance traveled, number of entries into, and time spent in the center of the locomotor arena. Novel object recognition was performed as previously described (Bevins and Besheer, 2006) . Results were recorded as an object discrimination ratio (ODR), which is calculated by dividing the time the mice spent exploring the novel object by the total amount of time exploring the two objects.
Fear conditioning. Our conditioning chamber was in a soundattenuating box. A clear Plexiglas window allowed the experimenter to film the mouse performance with a camera placed on a tripod and connected to the Freeze-frame software (MED Associates). To provide background white noise (72 dB), a single computer fan was installed in one of the sides of the sound-attenuating chamber. The conditioning chamber had a 36 bar insulated shock grid floor. The floor was removable, and after each experimental subject, we cleaned it with 75% ethanol and then with water. Mice were handled once a day for 3 d before behavioral experiments. Only one animal at a time was present in the experimentation room. For the cued and contextual conditioning experiments, mice were placed in the conditioning chamber for 2 min before the onset of a discrete tone [conditioned stimulus (CS)] (a sound that lasted 30 s at 2800 Hz and 85 dB). In the last 2 s of the CS, mice were given a foot shock [unconditioned stimulus (US)] of 0.50 mA for 2 s through the bars of the floor, except in an experimental series in which we used 0.75 mA to elicit more memory. After the CS/US pairing, the mice were left in the conditioning chamber for another 30 s and were then placed back in their home cages. Freezing behavior, defined as the absence of all movement except for that necessitated by breathing, was scored using the Freezeview software. To evaluate contextual fear learning, freezing was measured for 5 min (consecutive) in the chamber in which the mice was tested 24 h after training. To evaluate cued fear learning, after contextual testing, the mice were placed in a novel context (triangular cage with smooth flat floor and with vanilla odorant) for 2 min (pre-CS test), after which they were exposed to the CS for 3 min (CS test), and freezing was measured. Sensory perception of the shock was determined through threshold assessment. A sequence of single foot shocks was delivered to animals placed on the same electrified grid used for fear conditioning. Initially, a 0.1 mV shock was delivered for 1 s, and the animal behavior was evaluated for flinching, jumping, and vocalization. At 30 s intervals, the shock intensity was increased by 0.1 mV to 0.7 mV and then returned to 0 mV in 0.1 mV increments at 30 s intervals. Threshold to vocalization, flinching, and then jumping was quantified for each animal by averaging the shock intensity at which each animal manifests a behavioral response to the foot shock.
Statistical analysis. For mice behavioral studies, all data are shown as mean Ϯ SEM. Experiments were performed in blind for genotype. Statistical tests included using a Student's t test and a p Ͻ 0.05 was considered significant. For the biochemical studies, all quantified data represent an average of at least triplicate samples. Error bars represent SEM.
Results

Generation of FBD KI mice
We generated a targeting vector for the introduction of the British mutation in the Bri2 mouse gene. The vector uses the floxed PGK-neo selection cassette and contains a 5Ј homologous region and the negative selection cassette, PGK-dt. The 3Ј homologous region introduces the FBD mutation into the Bri2 mouse gene (Fig. 1 A) . To humanize the mouse COOH-terminal region of Bri2, an alanine was substituted for threonine (T) at codon 250. The linearized targeting vector was transfected into 129 ES cells by electroporation and ES cell clones carrying the proper homologous recombination and the tABri (targeted ABri) allele were identified by PCR for 5Ј region (i.e., Left Arm: if homologous recombination had occurred these primers would amplify a product of ϳ1.67 kb) and for the 3Ј region (i.e., Right Arm: if homologous recombination had occurred these primers would amplify a product of ϳ3.4 kb). Of the ϳ600 screened ES clones, we found 3 clones in which the British mutation was inserted in one of the Bri2 alleles, Bri2
ABri/ϩ 82, and Bri2 tABri/ϩ 197 as shown in Figure 1 B. The occurrence of homologous recombination was confirmed by sequencing the PCR products and by performing Southern blot analysis (Fig. 1C) . DNA derived from individual Bri2 tABri/ϩ ES clones was digested with BamHI, gel separated, blotted into a nylon membrane, and hybridized with either the 5Ј or the 3Јprobe. The 5Ј probe hybridizes with a ϳ11.9 kb fragment derived from the wild-type locus. Homologous recombination at the 5Ј homologous region yields a ϳ8.9 kb fragment upon BamHI digestion due to the introduction of the BamHI site in the PGK-neo selection cassette. ES clones Bri2 tABri/ϩ 57, Bri2 tABri/ϩ 82, and Bri2 tABri/ϩ 197 carry a wild-type allele (11.9 kb) and a recombined allele (8.9 kb). The 11.9 kb and 8.9 kb bands had a similar intensity, indicating that 50% of the Bri2 alleles are wild type and 50% are recombined, and proving that the ES cells we have selected are clonal populations. Similar results were obtained when homologous recombination at the 3Ј site was assessed (data not shown). In this case the 3Ј probe detected a wild-type ϳ11.9 kb fragment and a recombinant 4.7 kb fragment, due to the introduction of the BamHI site. For subse-quent analysis, only the Bri2 tABri/ϩ 57 and 82 clones are considered here. These two British ES cell clones (129, agouti coat color), carrying the correct site-specific homologous recombination, were injected into C57BL/6J blastocysts (black coat color). The resulting chimeras with a high proportion of agouti coat color (i.e., with a high relative contribution from the injected ES cells) were backcrossed to C57BL/6J mice to obtain heterozygous Bri2 tABri/wt , which were identified by PCR and Southern analysis as described above (data not shown) using tail DNA. The Neo cassette was deleted by crossing Bri2 tABri/wt mice to Meu40-Cre mice. In this article we will use FBD KI to indicate mice that have, like the human patients, one WT Bri2 allele and a mutant one, and FBD KI/KI to indicate mice with both Bri2 alleles mutated.
General characteristics and pathology of the FBD KI/KI mice
Mice presented with no growth abnormalities and thrived at appropriate age, as their wild-type littermates. Animals were active and alert, and they presented in good body condition with adequate body fat. Overall, these mice have lesions that are commonly found in older mice and are considered age-related, spontaneous lesions and are within the normal limits for age-related lesions.
FBD KI/KI mice do not present FBD-related neuropathology
Brain sections of 18-month-old mice were first examined for FBD-related pathology. For comparison, we included sections of a patient with FBD (Holton et al., 2001) . No staining of vascular amyloid, plaques, or diffuse deposits was observed in knock-in mice by ThS (Fig. 2 A) or by using the anti-ABri antibody 1705 (Fig. 2C ). An affected blood vessel from an FBD patient stained with ThS (Fig. 2 B) and immunostained with antibody 1705 (Fig.  2 D) are shown for comparison. Immunostaining using anti-GFAP antibodies did not reveal significant differences between WT mice (Fig. 2 F) and FBD KI/KI mice (Fig. 2G ) in activated astrocytes. No significant differences between WT and FBD KI/KI were observed after staining with antibody 5D4 (data not shown) and IbA1 (Fig. 2G , FBD KI/KI ; H, WT; hippocampi shown) for the detection of activated microglia. When searching for clues of neuronal loss, we did not find any weakening of NeuN signal, as shown in samples form hippocampi of FBD KI/KI (Fig. 2 I, K ) compared with control ( Fig. 2 J, L) mice. H&E staining of FBD KI/KI mice showed no significant loss of neurons or noticeable malformations compared with WT littermates. These results indicated that the brain of FBD KI/KI mice maintained normal morphology of aged mice and were free of ABri deposits at 18 months of age.
Tau pathology, i.e., hyperphosphorylation and tangle formation, is a known characteristic of BRI2-associated dementias (Vidal et al., 1999 (Vidal et al., , 2000 and generally correlates better than amyloid deposition with cognitive deficits in dementias. Thus, we investigated whether FBD mice bear such features.
Immunostaining of 18-month-old FBD KI/KI and control mice with a total Tau antibody (DA9) showed a neuronal cytoplasmic staining in most areas of the brain, including the cerebellum and brainstem (data not shown), hippocampus (Fig. 3A , FBD KI/KI ; B, WT) and temporal subcortical region (Fig. 3C, FBD KI/KI; D, WT) . No difference was observed between FBD KI/KI and control mice. The staining with CP13, an antibody that recognize the "early" Tau phosphorylation site Ser 202, was similar to that seen with DA9 in the hippocampus (Fig. 3E , FBD KI/KI ; F, WT) and entorhinal cortex (Fig. G , FBD KI/KI ; H, WT) and other areas (cerebellum, olfactory bulb, brainstem: not shown). No axonal staining was observed and no significant difference was noted between FBD KI/KI and control mice. PHF1 antibody ("late" Ser396/404 phosphorylation) showed a more marked staining of neurons, and possibly oligodendrocytes, with more axonal involvement, with a similar pattern in both FBD KI/KI and controls (Fig. 3I ,J, hippocampus of FBD KI/KI and WT respectively; K,L, temporal cortical and subcortical area of FBD KI/KI and Wt respectively; cerebellum, brainstem and olfactory bulb not shown). No significant differences were observed using commercially available antibody AT8 (data not shown).
Biochemical analysis of Tau accumulation and phosphorylation was performed by means of ELISA (Fig. 3M ) and Western blot (Fig.  3N ) on 6-month-old FBD KI mice. Total Tau (DA9), pSer202Tau (CP13), pThr231Tau (CP17 and CP9), and pSer396/404Tau (PHF1) were not different in the 4 analyzed FBDKI mice compared with 4 littermates. Altogether, these data point toward a normal "aging" pattern, as far as Tau and its modifications are concerned in FBDKI/KI and FBDKI mice, similar to what is seen in WT littermates.
Levels of BRI2 protein are reduced in human FBD brains and in synapses of FBD KI mice
Analysis of normal human brain samples and a sample from an FBD patient (kindly provided by Dr. Jorge Ghiso, New York University School of Medicine, New York, NY) showed reduced BRI2 levels in the British dementia case (Fig. 4 A) . Next, we studied FBD KI mice, which faithfully reproduce the genetic defect of FBD patients since they carry one allele coding for WT Bri2 and the other coding for Bri2-ABri. In FBD KI mice, mBri2 levels were dramatically reduced, similar to what is seen in human brains (Fig. 4B) . Quantification of the triplicate data indicates that the reductions are significant (S1, p ϭ 0.0059; LP1, p ϭ 0.0024), These differences are not due to defective transcription/ splicing of the mutant allele since ϳ50% of the Bri2 mRNA coded for the mutant protein in the FBD KI brains (data not shown). These data indicate that the FBD mutation compromises formation of mBRI2 in vivo. It will be important to analyze the biochemical mechanism by which the British mutation causes a reduction in mBRI2 level. Preliminary data suggest that the mutation affects trafficking of the mutant protein out of the endoplasmic reticulum and may target the protein for degradation.
Loss of memory is a clinical hallmark of FBD, and Ramon y Cajal (1911) predicted that dementia results from the weakening of synapses. We have, therefore, investigated whether Bri2 is expressed in synaptic termini. Interestingly, we found that while Bri2 is enriched in synaptic membranes in WT mice (LP1, Fig.  4C ), Bri2 is substantially reduced in synaptic membranes isolated from FBD KI mice (Fig. 4 D) .
FBD KI mice present memory deficits
Although FBD KI mice do not present neuropathological lesions, the reduction in mBri2 protein found in synaptic preparation of FBD KI animals prompted us to examine whether FBD KI mice presented signs of cognitive impairments by testing behavior and memory. Since the genetic background heavily influences behavioral tests, FBD KI mice were backcrossed to C57BL/6J mice for 15 generations before performing behavioral tests. In addition, only male mice were used to avoid problems due to menstrual cyclerelated hormonal changes in females. Open field is a sensorimotor test for locomotor, habituation, exploratory, and emotional behavior, including risk assessment and anxiety-like behavior, in novel environments. The number of entries into the center and time spent in the center are indicators of anxiety levels. The more the mouse enters the center and explores it, the lower the level of anxiety-like behavior. Since the FBD KI mice are similar to the WT mice ( p ϭ 0.83 for number of entries into the center, and p ϭ 0.67 for the time spent in the center), there is no deficit or excess of anxiety. Due to the similar total track lengths ( p ϭ 0.94) the FBD KI mice have no deficit in locomotor behavior and habituation. These defects would have prevented us from performing memory tests on these animals. Following the open field test, the same bin was used to put the FBD KI and WT mice through a novel object recognition (NOR) behavior test to begin assessing memory. NOR is a nonaversive task that relies on the mouse's natural exploratory behavior. During the training session, both the FBD KI and WT mice spent the same amount of time exploring the two identical novel objects (Fig. 5A) . The following day, when a novel object was introduced, the FBD KI mice still spent the same amount of time exploring the two objects as if they were both novel to them, while the WT mice spent more time exploring the novel object compared with the object used 24 h prior, as expected (Fig. 5B) . This finding indicate that memory is impaired in FBD KI mice in an ethologically relevant, nonaversive behavioral context. Next, we tested whether the mice had any deficits that would prevent them from completing a spatial working memory test such as the radial-arm water maze (RAWM) test, which depends upon hippocampal function (Diamond et al., 1999) . Testing with the visible platform showed no difference in the time needed to find the platform and swimming speed . FBD KI/KI (C) and control mice (D) also show similar Tau immunoreactivity in gray and white matter of the temporal lobe. E, F, Hippocampi of FBD KI/KI mice (E) and control mice (F ) show CP13 cytoplasmic staining, with some neurons showing initial neuritic involvement, without significant difference between the knock-in and the WT animals. G-L, Similarly, the entorhinal cortex (G, FBD KI/KI ; H, WT) shows CP13 immunostaining, with no difference between the genotypes. PHF staining was not different in FBD KI/KI and control mice in the hippocampus (I, FBD KI/KI ; J, WT) with rare neuritc staining (insets), in the temporal cortical and subcortical region (K, FBD KI/KI ; L, WT). Scale bars: A-L,50m. M, Quantification of total Tau (DA9) and of 3 Tau phosphorylation sites (CP13: pSer202; CP17: pThr231; PHF1: pSer396/Ser404) by sandwich ELISA shows no significant difference in whole forebrains from FBD KI and control mice at 24 months of age. N, Western blot analysis of 4 FBD KI mice and 4 control littermates, at 6 months, fails to show differences in total Tau and 3 phosphorylation sites (CP13: pSer202; CP9: pThr231; PHF1: pSer396/Ser404) in these mice.
between the two groups [FBD KI and WT mice have similar speed ( p ϭ 0.19) and need similar time ( p ϭ 0.98) to reach a visible platform at the age tested] and found that there were no deficits in vision, motor coordination, or motivation in the FBD KI mice compared with WT littermates. In the RAWM, mice are required to learn and memorize the location of a hidden platform in one of the arms of a maze with respect to spatial cues. WT mice were able to acquire (A) and retain (R) memory of the task. Striking differences were seen with 9-month-old FBD KI mice, which showed severe abnormalities during acquisition, A3 ( p ϭ 0.027) and A4 ( p ϭ 0.0089) and retention of the task ( p Ͻ 0.0001) (Fig. 6 ). The differences were not due to impairment of speed or vision, as stated above, indicating that FBD KI mice have severe impairment in spatial memory for platform location during both acquisition and retention of the task.
We used another test of hippocampus-dependent memory: fear-conditioning learning. The fear-conditioning learning paradigm depends on the hippocampus and amygdala. The hippocampus, in particular, is indispensable for contextual fear conditioning (Phillips and LeDoux, 1992) , a form of associative learning in which mice must associate a neutral stimulus with an aversive one. This type of cognitive test is more rapid than other behavioral tasks that require multiple days of training and testing. In a series of preliminary experiments, we tested whether the FBD KI and WT mice had different perceptions of an electric shock. We found that the shock threshold was the same for mice of the different genotypes (data not shown). Next we examined contextual fear conditioning. FBD KI and WT littermates 9 months of age were subjected to a standard fear-conditioning paradigm (Bourtchuladze et al., 1994) . The animals were placed in a novel context (fear-conditioning box) and were exposed to a tone (conditioned stimulus [CS]) paired with a mild foot shock (unconditioned stimulus [US]) (training phase of the fear conditioning). Conditioning was assessed 24 h later by measuring "freezing" behavior-the absence of all movement except for that necessitated by breathing-in response to the context (contextual conditioning) or the auditory cue (CS) within a completely different context (cued conditioning). During the training phase, we found no difference in the freezing of FBD KI and WT littermates mice (Fig. 7A) . A Student's t test revealed no significant difference between the 2 groups ( p ϭ 0.19). Twenty-four hours later we found a decrease in the freezing time of FBD KI mice compared with that of WT littermates in contextual conditioning (Fig. 7A) . We next tested cued fear conditioning, a hippocampusindependent task (Phillips and LeDoux, 1992) , and did not find a difference in freezing behavior between the 2 groups (Fig. 7B) . This result suggests that the amygdala, which is involved mainly in cued conditioning, is not impaired in these mice. These findings indicate that FBD KI mice have a selective hippocampusdependent impairment in associative learning. Altogether these data show that depletion of Bri2 is associated with impaired memory in FBD KI mice.
Reduction of Bri2 levels results into cognitive loss similar to that seen in FBD KI mice. The data show that memory deficits in FBD KI mice correlate with depletion of mBri2 from synapses rather than cerebral amyloidosis and tauopathy, suggesting that clinical dementia occurs independently of pathological lesions in FDD and via loss of function mechanisms. To further test the hypothesis that British dementia is caused by loss of BRI2 function, we analyzed Bri2 haplodeficient mice Matsuda et al., 2008) . These mice express reduced mBri2 levels and do not produce any ABri peptide. Notably, Bri2 ϩ/ Ϫ animals show memory impairments similar to FBD KI mice ( Fig. 8 A-D) , further suggesting that loss of Bri2 function rather than the ABri peptide causes memory deficits in FBD KI mice. Western blot analysis confirms that the synaptic levels of mBri2 are reduced in Bri2 haplodeficient mice (Fig. 8 E) . Quantification of the data indicate that, if an arbitrary value of 100 is assigned to protein levels in WT samples, the values of Bri2 are 100 Ϯ 3.27 for the WT vs 39.28 Ϯ 9.09 for the Bri2 ϩ/Ϫ samples ( p ϭ 0.0033). APP levels are instead similar in the two genotypes ( p ϭ 0.73).
Discussion
In this manuscript we characterize a KI model for FBD. Mouse models for human dementias are conventionally based on a transgenic approach in which human mutant proteins that cause familial forms of dementia are overexpressed under the control of brainspecific promoters (Price et al., 2000; LaFerla and Oddo, 2005; McGowan et al., 2006) . The transgenic approach is predicated on the amyloid cascade hypothesis, which deems essential the reproduction of cerebral amyloidosis when modeling dementia in mice. Transgenic models are, however, genetically un-congruous with the human diseases and, in addition, the mutant transgene is expressed in an artificial quantitative-spatio-temporal manner. On the contrary, in the KI mice, the pathogenic human mutation is inserted in the mouse allele, and KI models are genetically faithful to the human pathology. However, the KI model does not successfully reproduce in mice the neuropathological lesions observed in humans affected by the disease. This limitation is critical if development of amyloid plaques and neurofibrillary tangles is directly related to the cognitive and behavioral changes associated with human dementia (Hardy and Selkoe, 2002; St George-Hyslop and Petit, 2005; Garringer et al., 2009) . Analyzing memory in the FBD KI model, which does not present any detectable neuropathological lesions such as cerebral amyloidosis and tauopathy, allows us to directly test this hypothesis. Our results quite strikingly show that FBD KI mice present severe memory impairments already at 9 months of age. We tested hippocampus-dependent memory using 2 different assays: spatial working memory and fear-conditioning learning. Examination of spatial working memory, a type of short-term memory that can be studied with the RAWM test, showed significant deficits in FBD KI mice, both in the acquisition and retention phase of the task. Notably, shortterm memory is affected at early stages in AD (Welsh et al., 1991 (Welsh et al., , 1992 . FBD KI mice also have a selective hippocampus-dependent impairment in associative learning. Interestingly, the amygdala, which is involved mainly in cued conditioning, is not impaired in these mice. FBD KI and WT mice were also subjected to a novel object recognition behavior, which assesses a different type of memory. NOR is a nonaversive task that relies on the mouse natural exploratory behavior and showed that memory is impaired in FBD KI mice in an ethologically relevant, nonaversive behavioral context. Remarkably, these memory deficits are associated with depletion in mBri2 protein levels in FBD KI mice. This reduction in mBri2 is not an artifact of the mouse system since brain from a human FBD case shows a similar mBRI2 lowering. Remarkably, Bri2 ϩ/ Ϫ mice show cognition defects similar to those seen in FBD KI mice. Bri2 ϩ/ Ϫ mice present deficits in spatial working memory, explorative memory and associative learning, while the amygdala is not impaired. Altogether, the data are consistent with the supposition that loss of function (Saura et al., 2004; De Strooper et al., 2007) plays a prominent role in the pathogenesis of FBD, even though we cannot exclude that untraceable amounts of neurotoxic ABri peptides could contribute to the pathology. Interestingly, the FDD KI mice that we have developed (Giliberto et al., 2009 ), present memory deficits ϩ/Ϫ mice present cognition deficits similar to those of FBD KI mice. A, Seven-month-old Bri2 ϩ/ Ϫ mice present spatial working memory deficits [no difference was found at A1 ( p ϭ 0.58) and A2 (0.076), however, a significant difference was seen at A3 ( p ϭ 0.0019), at A4 ( p ϭ 0.0008), and the retention trail (R) ( p Ͻ 0.0001). B, Seven-month-old Bri2 ϩ/ Ϫ animals have a defect in object recognition memory. C, Bri2 ϩ/ Ϫ and WT littermates show similar freezing during cued conditioning (both in the pre-CS group, p ϭ 0.96, and in the CS group, p ϭ 0.94). D, Bri2 ϩ/ Ϫ and WT littermates show no difference in freezing during training (baseline; p ϭ 0.8), whereas contextual fear conditioning performed 24 h after training shows a reduction of freezing responses in Bri2 ϩ/ Ϫ mice compared with WT littermates [the freezing time of Bri2 ϩ/ Ϫ mice was ϳ50% of WT mice; n ϭ 8 males, WT littermates, n ϭ 8 males ( p ϭ 0.0021). *p Ͻ 0.002; **p Ͻ 0.001; ***p Ͻ 0.0001. E, Bri2 levels are reduced in synaptic fractions (LP1) of Bri2 ϩ/Ϫ mice compared with littermates. The absence of the signal in Bri2 Ϫ/Ϫ mice attests the specificity of the band. Levels of APP are comparable in all genotypes.
at as early as 6 months of age (Tamayev et al., 2010) , although the mice have no cerebral amyloidosis, tauopathy and reactive glyosis even at 18 months of age. Vidal et al. (2009) have previously described a transgenic mouse overexpressing the Danish BRI2 mutant, called tg-FDD, characterized by the presence of widespread cerebral amyloid angiopathy and parenchymal amyloid deposition of ADan peptide. Given the presence of defects in locomotor behavior, the authors could not however analyze cognition and memory in tg-FDD mice. More recently, another FDD transgenic model with ADan deposition (called ADanPP-Tg mice) has been described (Coomaraswamy et al., 2010) . Notably, ADanPP-Tg mice failed to develop mixed ADan/A␤ plaques, which are the type of lesions present in FDD patients (Vidal et al., 2000) , even when crossed to A␤-depositing mice. On the contrary, the Danish BRI2 mutant strongly reduced A␤ plaques in double transgenic mice, similarly to what previously shown for wild-type BRI2 (Kim et al., 2008; Matsuda et al., 2008) . These data indicate that the amyloid lesion in ADanPP-Tg mice are different from those present in FDD patients and confirm an inhibitory effect of BRI2 on A␤ production (Matsuda et al., 2008) . ADanPP-Tg mice do not show cognitive and memory defects in the first 12 months of life despite considerable amyloid load. At older ages, ADanPP-Tg mice show deficits with the cue navigation task of the Morris water maze associated with increase of thigmotaxis and passive floating, lower speed, less body weight and an anxiety-related phenotype. These anomalies make assessment of cognition and memory in old ADanPP-Tg mice not doable (Coomaraswamy et al., 2010) .
The FBD KI mice must produce the ABri peptide, as indicated by the fact that a small fraction of mutant Bri2 undergoes maturation in mice with two mutant copies of the Itm2b/Bri2 gene (data not shown). Even if our results suggest that ABri does not cause memory deficits, it is possible that ABri may set off other clinical symptoms of FBD patients, such as progressive ataxia, that are not replicated in FBD KI mice.
The synaptic function(s) of mBri2 will have to be clarified and whether deregulation of this function(s) cause synaptic plasticity and memory deficits in FBD KI mice will need further investigation. Several recent papers have established an interesting link between BRI2 and APP (Fotinopoulou et al., 2005; Kim et al., 2008; Matsuda et al., 2005 Matsuda et al., , 2008 Matsuda et al., , 2009a . Thus, it will be interesting to address whether alterations of this BRI2 function causes memory loss in British dementia. In conclusion, we present here a genetically congruous mouse model of Familial British Dementia with memory deficits. Analysis of this model indicates that amyloid deposition and tangles formation may follow rather than cause clinical dementia in FBD, contradicting the amyloid cascade hypothesis.
